Navigation Links
Venlafaxine extended-release effective for patients with major depression

Philadelphia, PA, December 12, 2007 Major depressive disorder (MDD) is the most common major mental illness, afflicting almost one in five individuals. More than 75% of people who recover from an episode of MDD will have at least one recurrence, with the majority having multiple recurrences. MDD is the leading cause of disability of all medical illnesses, with substantial functional impairment, morbidity, and mortality. Few studies have assessed the efficacy of antidepressant medications beyond 1 year of maintenance treatment for the prevention of recurrent depression. However, a new study being published in the upcoming December 15th issue of Biological Psychiatry has done just that.

The PREVENT study, an acronym for the title of the study The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years study, is, according to one of the senior authors on the paper, Dr. Martin B. Keller, a multiphase, double-blind, randomized clinical trial designed to investigate the efficacy of the serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine extended release in the prevention of depressive recurrence over 2 years in patients with a history of recurrent MDD who have responded to acute and continuation treatment. The investigators randomly assigned patients with recurrent depression to receive treatment with either venlafaxine extended-release (ER) or fluoxetine, an antidepressant already established as efficacious as a comparative medication. Although the PREVENT study followed patients for over two years, this article reports only on the acute and continuation phases, which were 10 weeks and 6 months long respectively.

Dr. Keller notes that this study has several novel aspects to its design and methods, including its very large sample size, and long period of blinded treatment, where neither the physicians nor patients knew which medication the patient was receiving. The authors found that nearly 80% of the patients achieved at least an adequate therapeutic response to acute phase treatment with venlafaxine ER or fluoxetine, and almost none of the responders who continued on treatment for 6 months relapsed.

Husseini K. Manji, M.D., FRCP(C), Deputy Editor of Biological Psychiatry and Director of the Mood and Anxiety Disorders Program at the National Institute of Mental Health, comments on the studys findings:

"Major depression is a serious, debilitating, life-shortening illness that affects millions of people worldwide. This is thus an important study that shows surprisingly high response and remission rates. For many patients, major depression is a chronic illness characterized by multiple episodes of symptom exacerbation, residual symptoms between episodes, and functional impairment. Thus, the ability to maintain patients in remission is critical to reducing long-term disability."

In addition to the high response rates by the patients in this study, the rates of adverse events (side effects) were similar among the two treatment groups. Dr. Manji does issue a caution though with regard to generalizing the findings, noting that the investigators studied a group of patients whose course of illness was not chronic. Furthermore, they excluded patients with a history of treatment resistance or significant comorbid illnesses. However, he added that if replicated, the results suggest that there may be a subgroup of depressed patients for whom early and sustained treatment can maintain response and prevent relapses." Dr. Keller remarks that these results are critical to clinical practice and should be considered when choosing a treatment for patients with recurrent MDD.


Contact: Jayne Dawkins

Related medicine news :

1. Flynn Pharma Acquires Rights From Pacira Pharmaceuticals to DepoDur(R), the Only Extended-Release Epidural Opioid for Post-Operative Pain, in Europe
2. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
3. New treatment effective in counteracting cocaine-induced symptoms
4. Use of certain lipid measures not more effective in predicting coronary heart disease
5. HPV vaccine does not appear to be effective for treating pre-existing HPV infection
6. Effectiveness of mouse breeds that mimic Alzheimers disease symptoms questioned
7. Stanford study highlights cost-effective method of lowering heart disease risks
8. Jefferson specialists studying innovative surgery for effectively treating sleep apnea
9. Case Management Cost-Effective Way to Cut Heart Risks
10. ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.
11. Nasal Anthrax Vaccine Proves Effective in Animal Study
Post Your Comments:
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) will ... during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual ... F. Collen, a pioneer in the field of medical informatics, this prestigious award is ...
(Date:10/12/2017)... PA (PRWEB) , ... October 12, 2017 , ... ... is the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B ... York City on October 11, 2017. , The annual award competition recognizes editorial and ...
(Date:10/12/2017)... ... ... Health Literacy Innovations (HLI), creator of the Health Literacy ... Patient Education Network (CPEN), an independent professional organization that shares best practices in ... , As CPEN’s strategic partner, HLI will help support CPEN members by sharing ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... KALAMAZOO, Mich. , Sept. 18, 2017 ... , and OptiMed Specialty Pharmacy of Kalamazoo, ... offer a strategic hub service that expedites and streamlines ... personal spirometer, Spiro PD 2.0, and wellness management services.  ... is a medical device used to measure lung function ...
(Date:9/13/2017)... 2017   OrthoAtlanta has been named the official ... Committee (AFHC) for the 2018 College Football Playoff (CFP) National ... Mercedes-Benz Stadium in Atlanta, Georgia . OrthoAtlanta ... In" campaign, participating in many activities leading up to, and ... ...
(Date:9/12/2017)... 2017  Consumer reviews on the independent review site Consumer ... one company for hearing aids, ranking it higher than Miracle ... ... Consumers For Hearing Aids ... an online store that provides high performance, state-of-the-art, German-engineered hearing aids ...
Breaking Medicine Technology: